Su Jennifer A, Kelly Robert B, Grogan Tristan, Elashoff David, Alejos Juan C
Department of Pediatrics, Mattel Children's Hospital UCLA, Los Angeles, CA, USA.
Pediatr Transplant. 2015 Feb;19(1):68-75. doi: 10.1111/petr.12382. Epub 2014 Oct 27.
Mechanical circulatory support has been used for more than 30 yr to allow the heart to recover from ischemia and injury. There are limited pediatric data, however, on the efficacy of ECMO in the setting of post-transplantation support for primary graft dysfunction or rejection. Data from all patients at our university-affiliated, tertiary care children's hospital who underwent OHT between 1998 and 2010 and required subsequent ECMO support were analyzed. The primary outcome measure was survival to hospital discharge. Two hundred and three pediatric patients underwent OHT between 1998 and 2010 at our institution. Twenty-nine of these patients experienced post-transplantation cardiac failure requiring ECMO support, 18 of whom survived to hospital discharge (62%). Survival in the rejection and allograft vasculopathy group was 75%, and survival in patients with primary graft failure was 53% after ECMO support (p = 0.273). Patient survival to hospital discharge was not associated with ischemic time or duration of ECMO. ECMO provides hemodynamic support in the setting of cardiac failure and can be used successfully after pediatric OHT for primary graft dysfunction or rejection.
机械循环支持已使用超过30年,以使心脏从缺血和损伤中恢复。然而,关于体外膜肺氧合(ECMO)在原发性移植物功能障碍或排斥反应的移植后支持中的疗效,儿科数据有限。分析了1998年至2010年间在我们大学附属的三级护理儿童医院接受心脏移植(OHT)并需要后续ECMO支持的所有患者的数据。主要结局指标是存活至出院。1998年至2010年间,我们机构有203名儿科患者接受了心脏移植。其中29名患者出现移植后心力衰竭,需要ECMO支持,其中18名存活至出院(62%)。在接受ECMO支持后,排斥反应和移植血管病变组的存活率为75%,原发性移植物功能衰竭患者的存活率为53%(p = 0.273)。患者存活至出院与缺血时间或ECMO持续时间无关。ECMO在心力衰竭情况下提供血流动力学支持,并且在儿科心脏移植后可成功用于原发性移植物功能障碍或排斥反应。